Publication Date:
2015-06-06
Description:
The discovery of Streptomyces-produced streptomycin founded the age of tuberculosis therapy. Despite the subsequent development of a curative regimen for this disease, tuberculosis remains a worldwide problem, and the emergence of multidrug-resistant Mycobacterium tuberculosis has prioritized the need for new drugs. Here we show that new optimized derivatives from Streptomyces-derived griselimycin are highly active against M. tuberculosis, both in vitro and in vivo, by inhibiting the DNA polymerase sliding clamp DnaN. We discovered that resistance to griselimycins, occurring at very low frequency, is associated with amplification of a chromosomal segment containing dnaN, as well as the ori site. Our results demonstrate that griselimycins have high translational potential for tuberculosis treatment, validate DnaN as an antimicrobial target, and capture the process of antibiotic pressure-induced gene amplification.〈br /〉〈span class="detail_caption"〉Notes: 〈/span〉Kling, Angela -- Lukat, Peer -- Almeida, Deepak V -- Bauer, Armin -- Fontaine, Evelyne -- Sordello, Sylvie -- Zaburannyi, Nestor -- Herrmann, Jennifer -- Wenzel, Silke C -- Konig, Claudia -- Ammerman, Nicole C -- Barrio, Maria Belen -- Borchers, Kai -- Bordon-Pallier, Florence -- Bronstrup, Mark -- Courtemanche, Gilles -- Gerlitz, Martin -- Geslin, Michel -- Hammann, Peter -- Heinz, Dirk W -- Hoffmann, Holger -- Klieber, Sylvie -- Kohlmann, Markus -- Kurz, Michael -- Lair, Christine -- Matter, Hans -- Nuermberger, Eric -- Tyagi, Sandeep -- Fraisse, Laurent -- Grosset, Jacques H -- Lagrange, Sophie -- Muller, Rolf -- Howard Hughes Medical Institute/ -- New York, N.Y. -- Science. 2015 Jun 5;348(6239):1106-12. doi: 10.1126/science.aaa4690.〈br /〉〈span class="detail_caption"〉Author address: 〈/span〉Department of Microbial Natural Products, Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), Helmholtz Centre for Infection Research and Pharmaceutical Biotechnology, Saarland University, 66123 Saarbrucken, Germany. German Centre for Infection Research (DZIF), Partner Site Hannover-Braunschweig, Hannover, Germany. ; Department of Microbial Natural Products, Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), Helmholtz Centre for Infection Research and Pharmaceutical Biotechnology, Saarland University, 66123 Saarbrucken, Germany. German Centre for Infection Research (DZIF), Partner Site Hannover-Braunschweig, Hannover, Germany. Helmholtz Centre for Infection Research (HZI), 38124 Braunschweig, Germany. ; Center for Tuberculosis Research, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA. KwaZulu-Natal Research Institute for Tuberculosis and HIV (K-RITH), Durban 4001, South Africa. ; Sanofi-Aventis R&D, LGCR/Chemistry, Industriepark Hochst, 65926 Frankfurt am Main, Germany. ; Sanofi-Aventis R&D, Infectious Diseases Therapeutic Strategic Unit, 31036 Toulouse, France. ; Sanofi-Aventis R&D, Strategy, Science Policy & External Innovation (S&I), 75008 Paris, France. ; Helmholtz Centre for Infection Research (HZI), 38124 Braunschweig, Germany. Sanofi-Aventis R&D, LGCR/Chemistry, Industriepark Hochst, 65926 Frankfurt am Main, Germany. ; Sanofi-Aventis R&D, Infectious Diseases Therapeutic Strategic Unit, 65926 Frankfurt, Germany. ; German Centre for Infection Research (DZIF), Partner Site Hannover-Braunschweig, Hannover, Germany. Helmholtz Centre for Infection Research (HZI), 38124 Braunschweig, Germany. ; Sanofi-Aventis R&D, Disposition Safety and Animal Research, 34184 Montpellier, France. ; Center for Tuberculosis Research, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA. ; Department of Microbial Natural Products, Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), Helmholtz Centre for Infection Research and Pharmaceutical Biotechnology, Saarland University, 66123 Saarbrucken, Germany. German Centre for Infection Research (DZIF), Partner Site Hannover-Braunschweig, Hannover, Germany. rolf.mueller@helmholtz-hzi.de.〈br /〉〈span class="detail_caption"〉Record origin:〈/span〉 〈a href="http://www.ncbi.nlm.nih.gov/pubmed/26045430" target="_blank"〉PubMed〈/a〉
Keywords:
Animals
;
Antitubercular Agents/chemistry/*pharmacology/therapeutic use
;
Bacterial Proteins/*antagonists & inhibitors
;
Cell Line, Tumor
;
Crystallography, X-Ray
;
DNA-Directed DNA Polymerase
;
Disease Models, Animal
;
Drug Design
;
Humans
;
Mice
;
Microbial Sensitivity Tests
;
Molecular Sequence Data
;
*Molecular Targeted Therapy
;
Mycobacterium smegmatis/drug effects/enzymology
;
Mycobacterium tuberculosis/*drug effects/enzymology
;
Peptides, Cyclic/chemistry/*pharmacology/therapeutic use
;
Protein Structure, Secondary
;
Streptomyces/chemistry/drug effects/metabolism
;
Tuberculosis, Multidrug-Resistant/*drug therapy/microbiology
Print ISSN:
0036-8075
Electronic ISSN:
1095-9203
Topics:
Biology
,
Chemistry and Pharmacology
,
Computer Science
,
Medicine
,
Natural Sciences in General
,
Physics
Permalink
